HC Wainwright & Co. Maintains Buy on Aethlon Medical, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Aethlon Medical (NASDAQ:AEMD) but lowered the price target from $10 to $7.
June 24, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Aethlon Medical but lowered the price target from $10 to $7.
The maintained Buy rating suggests continued confidence in Aethlon Medical's prospects, but the lowered price target indicates tempered expectations for its short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100